Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

[Follicular hyperkeratosis in coeliac disease].

Ullrich N, Metze D, Luger TA, Böhm M.

Hautarzt. 2019 Jul;70(7):547-549. doi: 10.1007/s00105-019-4436-2. German. No abstract available.

PMID:
31161237
2.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.

Ständer S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, Luger TA; TCP-102 Study Group.

J Am Acad Dermatol. 2019 May;80(5):1395-1402. doi: 10.1016/j.jaad.2019.01.052. Epub 2019 Mar 17.

3.

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).

Tsianakas A, Zeidler C, Riepe C, Borowski M, Forner C, Gerss J, Metz M, Staubach P, Raap U, Kaatz M, Urban M, Luger TA, Ständer S.

Acta Derm Venereol. 2019 Apr 1;99(4):379-385. doi: 10.2340/00015555-3120.

4.

Melatonin and Its Metabolites Ameliorate UVR-Induced Mitochondrial Oxidative Stress in Human MNT-1 Melanoma Cells.

Kleszczyński K, Bilska B, Stegemann A, Flis DJ, Ziolkowski W, Pyza E, Luger TA, Reiter RJ, Böhm M, Slominski AT.

Int J Mol Sci. 2018 Nov 28;19(12). pii: E3786. doi: 10.3390/ijms19123786.

5.

Protection of glucotoxicity by a tripeptide derivative of α-melanocyte-stimulating hormone in human epidermal keratinocytes.

Gkogkolou P, Sarna M, Sarna T, Paus R, Luger TA, Böhm M.

Br J Dermatol. 2019 Apr;180(4):836-848. doi: 10.1111/bjd.17125. Epub 2018 Dec 3.

PMID:
30171686
6.

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.

Tsianakas A, Luger TA, Radin A.

Br J Dermatol. 2018 Feb;178(2):406-414. doi: 10.1111/bjd.15905. Epub 2018 Jan 11.

PMID:
28845523
7.

Novel insights into the pathogenesis of psoriasis.

Luger TA, Loser K.

Clin Immunol. 2018 Jan;186:43-45. doi: 10.1016/j.clim.2017.07.014. Epub 2017 Jul 21. Review. No abstract available.

PMID:
28736273
8.

Kongenitale Gefäß- und Pigmentmale mit Lymphödem, Beinlängendifferenz und Skoliose.

Convalexius P, Luger TA, Böhm M.

J Dtsch Dermatol Ges. 2017 Jul;15(7):751-754. doi: 10.1111/ddg.120_13075. No abstract available.

PMID:
28677192
9.

Congenital telangiectatic und pigmented lesions associated with lymphedema, difference in leg length, and scoliosis.

Convalexius P, Luger TA, Böhm M.

J Dtsch Dermatol Ges. 2017 Jul;15(7):751-753. doi: 10.1111/ddg.13075. Epub 2017 Jun 14. No abstract available.

PMID:
28612981
10.

Dihydroavenanthramide D inhibits mast cell degranulation and exhibits anti-inflammatory effects through the activation of neurokinin-1 receptor.

Lotts T, Agelopoulos K, Phan NQ, Loser K, Schmaus G, Luger TA, Ständer S.

Exp Dermatol. 2017 Aug;26(8):739-742. doi: 10.1111/exd.13265. Epub 2017 Mar 16.

PMID:
27892633
11.

Rosacea Management: Update on general measures and topical treatment options.

Schaller M, Schöfer H, Homey B, Hofmann M, Gieler U, Lehmann P, Luger TA, Ruzicka T, Steinhoff M.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:17-27. doi: 10.1111/ddg.13143. Review.

PMID:
27869379
12.

Pathogenese und Klinik der Rosazea als Schlüssel für eine symptomorientierte Therapie.

Reinholz M, Ruzicka T, Steinhoff M, Schaller M, Gieler U, Schöfer H, Homey B, Lehmann P, Luger TA.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:4-16. doi: 10.1111/ddg.13139_g. Review.

PMID:
27869378
13.

Aktueller Stand der systemischen Rosazea-Therapie.

Schaller M, Schöfer H, Homey B, Gieler U, Lehmann P, Luger TA, Ruzicka T, Steinhoff M.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:29-37. doi: 10.1111/ddg.13141_g. Review.

PMID:
27869375
14.

State of the art: systemic rosacea management.

Schaller M, Schöfer H, Homey B, Gieler U, Lehmann P, Luger TA, Ruzicka T, Steinhoff M.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:29-37. doi: 10.1111/ddg.13141. Review.

PMID:
27869374
15.

Rosazea-Management: Update über allgemeine Maßnahmen und topische Therapieoptionen.

Schaller M, Schöfer H, Homey B, Hofmann M, Gieler U, Lehmann P, Luger TA, Ruzicka T, Steinhoff M.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:17-28. doi: 10.1111/ddg.13143_g. Review.

PMID:
27869373
16.

Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy.

Reinholz M, Ruzicka T, Steinhoff M, Schaller M, Gieler U, Schöfer H, Homey B, Lehmann P, Luger TA.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:4-15. doi: 10.1111/ddg.13139. Review.

PMID:
27869372
17.

VORWORT.

Luger TA.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:3. doi: 10.1111/ddg.13142. No abstract available.

PMID:
27869371
18.

Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease.

Mykicki N, Herrmann AM, Schwab N, Deenen R, Sparwasser T, Limmer A, Wachsmuth L, Klotz L, Köhrer K, Faber C, Wiendl H, Luger TA, Meuth SG, Loser K.

Sci Transl Med. 2016 Oct 26;8(362):362ra146.

PMID:
27797962
19.

Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder.

Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, Luger TA, Deleuran M, Werfel T, Eyerich K, Stingl G; Councilors of the International Eczema Council.

J Invest Dermatol. 2017 Jan;137(1):18-25. doi: 10.1016/j.jid.2016.08.022. Epub 2016 Oct 20. Review.

20.

Lack of protection from development of multiple melanomas by an injected melanocortin analogue in a combined high-risk MC1R/CDKN2A genotype patient.

Böhm M, Jagirdar K, Sturm RA, König S, Bauer J, Metze D, Luger TA, Weishaupt C.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e65-e67. doi: 10.1111/jdv.13310. Epub 2015 Sep 2. No abstract available.

PMID:
26333485
21.

Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis.

Dosoki H, Stegemann A, Taha M, Schnittler H, Luger TA, Schröder K, Distler JH, Kerkhoff C, Böhm M.

Exp Dermatol. 2017 Jan;26(1):73-81. doi: 10.1111/exd.13180.

PMID:
27576129
22.

α-MSH modulates cell adhesion and inflammatory responses of synovial fibroblasts from osteoarthritis patients.

Böhm M, Apel M, Lowin T, Lorenz J, Jenei-Lanzl Z, Capellino S, Dosoki H, Luger TA, Straub RH, Grässel S.

Biochem Pharmacol. 2016 Sep 15;116:89-99. doi: 10.1016/j.bcp.2016.07.003. Epub 2016 Jul 7.

PMID:
27396757
23.

The tripeptide KdPT ameliorates ongoing psoriasis-like skin inflammation in murine and human skin.

Mykicki N, Klenner L, Baumann C, Auriemma M, Sternemann C, Soeberdt M, Elliott GR, Abels C, Luger TA, Loser K.

Exp Dermatol. 2017 Apr;26(4):328-334. doi: 10.1111/exd.13145. Epub 2016 Dec 9.

PMID:
27376341
24.

Regulation of melanocortin 1 receptor in allergic rhinitis in vitro and in vivo.

Kleiner S, Braunstahl GJ, Rüdrich U, Gehring M, Eiz-Vesper B, Luger TA, Steelant B, Seys SF, Kapp A, Böhm M, Hellings PW, Raap U.

Clin Exp Allergy. 2016 Aug;46(8):1066-74. doi: 10.1111/cea.12759. Epub 2016 Jun 15.

PMID:
27196703
25.

From morphology to biochemical state - intravital multiphoton fluorescence lifetime imaging of inflamed human skin.

Huck V, Gorzelanny C, Thomas K, Getova V, Niemeyer V, Zens K, Unnerstall TR, Feger JS, Fallah MA, Metze D, Ständer S, Luger TA, Koenig K, Mess C, Schneider SW.

Sci Rep. 2016 Mar 23;6:22789. doi: 10.1038/srep22789.

26.

Recommendations for managing cutaneous disorders associated with advancing age.

Humbert P, Dréno B, Krutmann J, Luger TA, Triller R, Meaume S, Seité S.

Clin Interv Aging. 2016 Feb 12;11:141-8. doi: 10.2147/CIA.S96232. eCollection 2016. Review.

27.

Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability.

Ständer S, Metz M, Ramos F MH, Maurer M, Schoepke N, Tsianakas A, Zeidler C, Luger TA.

Acta Derm Venereol. 2016 Aug 23;96(6):792-6. doi: 10.2340/00015555-2268.

28.

The skin in psoriasis: assessment and challenges.

Oji V, Luger TA.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S14-9. Epub 2015 Oct 15. Review.

PMID:
26472560
29.

The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis.

Tsianakas A, Luger TA.

Expert Opin Biol Ther. 2015;15(11):1657-60. doi: 10.1517/14712598.2015.1095887. Epub 2015 Oct 12.

PMID:
26457448
30.

Hypotrichosis, milia, brachydactyly, and frenula.

Jeskowiak A, Luger TA, Böhm M.

J Dtsch Dermatol Ges. 2015 Sep;13(9):934-6. doi: 10.1111/ddg.12759. Epub 2015 Jul 14. No abstract available.

PMID:
26177262
31.

Experimental Dermatology launches a new type of manuscript: 'BEDSIDE-TO-BENCH LETTER'.

Böhm M, Paus R, Luger TA.

Exp Dermatol. 2015 Sep;24(9):643. doi: 10.1111/exd.12795. No abstract available.

PMID:
26149539
32.

Cutaneous RANK-RANKL Signaling Upregulates CD8-Mediated Antiviral Immunity during Herpes simplex Virus Infection by Preventing Virus-Induced Langerhans Cell Apoptosis.

Klenner L, Hafezi W, Clausen BE, Lorentzen EU, Luger TA, Beissert S, Kühn JE, Loser K.

J Invest Dermatol. 2015 Nov;135(11):2676-2687. doi: 10.1038/jid.2015.225. Epub 2015 Jun 15.

33.
35.

L-Ascorbyl-2-phosphate attenuates NF-κB signaling in SZ95 sebocytes without affecting IL-6 and IL-8 secretion.

Ikeno H, Apel M, Zouboulis C, Luger TA, Böhm M.

Arch Dermatol Res. 2015 Sep;307(7):595-605. doi: 10.1007/s00403-015-1565-z. Epub 2015 Apr 18.

36.

NK-1 Antagonists and Itch.

Ständer S, Luger TA.

Handb Exp Pharmacol. 2015;226:237-55. doi: 10.1007/978-3-662-44605-8_14. Review.

PMID:
25861784
37.

Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy.

Zeidler C, von Köckritz A, Luger TA, Ständer S, Husstedt IW, Tsianakas A.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):1066-7. doi: 10.1111/jdv.13114. Epub 2015 Mar 19. No abstract available.

PMID:
25787234
38.

An α-MSH analog in erythropoietic protoporphyria.

Luger TA, Böhm M.

J Invest Dermatol. 2015 Apr;135(4):929-931. doi: 10.1038/jid.2015.16. No abstract available.

39.

Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis.

Schober SM, Peitsch WK, Bonsmann G, Metze D, Thomas K, Goerge T, Luger TA, Schneider SW.

J Dtsch Dermatol Ges. 2014 Dec;12(12):1112-9. doi: 10.1111/ddg.12520. English, German.

PMID:
25482694
40.

Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany.

Ständer S, Pogatzki-Zahn E, Stumpf A, Fritz F, Pfleiderer B, Ritzkat A, Bruland P, Lotts T, Müller-Tidow C, Heuft G, Pavenstädt HJ, Schneider G, Van Aken H, Heindel W, Wiendl H, Dugas M, Luger TA.

Acta Derm Venereol. 2015 Mar;95(3):266-71. doi: 10.2340/00015555-1949.

41.

Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study.

Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):468-73. doi: 10.1111/jdv.12585. Epub 2014 Aug 4.

PMID:
25087839
42.

Cutaneous manifestations of rheumatic diseases. Clinical presentation and underlying pathophysiology.

Gkogkolou P, Luger TA, Böhm M.

G Ital Dermatol Venereol. 2014 Oct;149(5):483-503. Epub 2014 Jul 31. Review.

PMID:
25077886
43.

Successful treatment of discoid lupus erythematosus with fumaric acid esters.

Tsianakas A, Herzog S, Landmann A, Patsinakidis N, Perusquía Ortiz AM, Bonsmann G, Luger TA, Kuhn A.

J Am Acad Dermatol. 2014 Jul;71(1):e15-7. doi: 10.1016/j.jaad.2013.12.004. No abstract available.

44.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, Wiendl H.

Ann Neurol. 2014 May;75(5):739-58. doi: 10.1002/ana.24165. Epub 2014 May 13.

PMID:
24771567
45.

Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.

Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, Augustin M, Luger TA, Ständer S.

Dermatology. 2013;227(4):353-60. doi: 10.1159/000355671. Epub 2013 Nov 23.

PMID:
24281309
46.

Is MC1 dispensable for regulation of cutaneous inflammatory and immune responses?

Böhm M, Luger TA, Steingräber AK, Goerge T.

Exp Dermatol. 2013 Dec;22(12):792-4. doi: 10.1111/exd.12263.

PMID:
24131319
47.

Inhibition of the prohormone convertase subtilisin-kexin isoenzyme-1 induces apoptosis in human melanoma cells.

Weiß N, Stegemann A, Elsayed MAT, Schallreuter KU, Luger TA, Loser K, Metze D, Weishaupt C, Böhm M.

J Invest Dermatol. 2014 Jan;134(1):168-175. doi: 10.1038/jid.2013.282. Epub 2013 Jun 27.

48.

Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.

Stegemann A, Sindrilaru A, Eckes B, del Rey A, Heinick A, Schulte JS, Müller FU, Grando SA, Fiebich BL, Scharffetter-Kochanek K, Luger TA, Böhm M.

Arthritis Rheum. 2013 Mar;65(3):792-804. doi: 10.1002/art.37809.

49.

Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.

Hofmann M, Salgo R, Aschoff R, Luger TA, Meurer M, Bräutigam M, Thaci D.

Arch Dermatol Res. 2013 Apr;305(3):215-21. doi: 10.1007/s00403-012-1297-2. Epub 2012 Dec 16.

PMID:
23242470
50.

[Evaluation of intra-organisational effects after use of certification programmes in hospital].

Neugebauer F, Schiller M, Luger TA, Hensen P.

Gesundheitswesen. 2013 Aug;75(8-9):e108-12. doi: 10.1055/s-0032-1329939. Epub 2012 Nov 22. German.

PMID:
23175164

Supplemental Content

Loading ...
Support Center